Feb 11 (Reuters) - Biohaven BHVN.N:
BIOHAVEN ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF TRORILUZOLE NEW DRUG APPLICATION FOR THE TREATMENT OF SPINOCEREBELLAR ATAXIA
BIOHAVEN LTD - FDA DECISION ON TRORILUZOLE NDA EXPECTED BY 3Q2025
BIOHAVEN LTD - PREPARED TO COMMERCIALIZE TRORILUZOLE FOR SCA IN 2025
Source text: ID:nPnsctV5a
Further company coverage: BHVN.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.